Case Control Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Aug 6, 2022; 10(22): 7686-7697
Published online Aug 6, 2022. doi: 10.12998/wjcc.v10.i22.7686
Comprehensive proteomic signature and identification of CDKN2A as a promising prognostic biomarker and therapeutic target of colorectal cancer
Qian-Qian Wang, Yuan-Chen Zhou, Yu-Jia Zhou Ge, Geng Qin, Teng-Fei Yin, Dong-Yan Zhao, Chang Tan, Shu-Kun Yao
Qian-Qian Wang, Yuan-Chen Zhou, Graduate School, Peking University China-Japan Friendship School of Clinical Medicine, Beijing 10029, China
Yu-Jia Zhou Ge, Dong-Yan Zhao, Graduate School, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China
Geng Qin, Shu-Kun Yao, Department of Gastroenterology, China-Japan Friendship Hospital, Beijing 100029, China
Teng-Fei Yin, Chang Tan, Graduate School, Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China
Author contributions: Wang QQ performed the study, analyzed the data, and drafted the manuscript; Zhou YC and Zhou Ge JY collected samples from subjects; Qin G provided guidance on experimental procedures; Yin TF, Zhao DY, and Tan C collected the clinical data; Yao SK supervised the study performance, revised the manuscript, and obtained the funding; and All authors read and approved the final manuscript.
Supported by National Key Development Plan for Precision Medicine Research, No. 2017YFC0910002.
Institutional review board statement: This study was approved by the Ethics Committee of China-Japan Friendship Hospital (No. 2018-116-K85).
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement, and the manuscript was prepared and revised according to the STROBE Statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shu-Kun Yao, MD, PhD, Professor, Department of Gastroenterology, China-Japan Friendship Hospital, No. 2 Yinghua East Road, Chaoyang District, Beijing 100029, China. shukunyao@126.com
Received: March 17, 2022
Peer-review started: March 17, 2022
First decision: May 12, 2022
Revised: May 19, 2022
Accepted: June 22, 2022
Article in press: June 22, 2022
Published online: August 6, 2022
Core Tip

Core Tip: In this study, quantitative proteomic analysis of colorectal cancer (CRC) was comprehensively performed, revealing many differentially expressed proteins that may be useful for mining novel targets. The results revealed the overexpression of thousands of tumor proteins, among which cyclin-dependent kinase inhibitor 2A (CDKN2A) was the highlight of this study, and high CDKN2A expression in CRC was significantly associated with poor prognosis and could serve as a powerful prognostic marker and precision therapeutic target.